This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Age...
Advice to medical device manufacturers - 2025 Timetable
Request for advice on the clinical development strategy and / or clinical invest...
Guide to manufacturers on the procedure for requesting advice from expert panels...
Human medicines European public assessment report (EPAR): Bridion, sugammadex, D...
Human medicines European public assessment report (EPAR): Izelvay, avacincaptad ...
Availability of medicines before and during crises
Human medicines European public assessment report (EPAR): Blitzima, rituximab, D...
Appendix 1: Acceptable intakes established for N-nitrosamines
Human medicines European public assessment report (EPAR): Enyglid, repaglinide, ...
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Pro...
Clinical Trials Information System (CTIS): training and support
Human medicines European public assessment report (EPAR): Vumerity, diroximel fu...
Questions and answers on implementation of the medical devices and in vitro diag...
Human medicines European public assessment report (EPAR): Quviviq, daridorexant,...
European Shortages Monitoring (ESMP) - Question and answer clinic for marketing ...